NASDAQ:SLDB - Solid Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$51.70 +2.64 (+5.38 %)
(As of 09/21/2018 03:46 AM ET)
Previous Close$49.06
Today's Range$49.18 - $54.54
52-Week Range$6.83 - $54.84
Volume305,600 shs
Average Volume308,367 shs
Market Capitalization$1.75 billion
P/E Ratio-17.91
Dividend YieldN/A
BetaN/A
Solid Biosciences logoSolid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SLDB
CUSIPN/A
Phone617-337-4680

Debt

Debt-to-Equity RatioN/A
Current Ratio18.97
Quick Ratio18.97

Price-To-Earnings

Trailing P/E Ratio-17.91
Forward P/E Ratio-23.39
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($1.73) per share
Price / Book-29.88

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees60
Outstanding Shares35,430,000
Market Cap$1.75 billion

Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc (NASDAQ:SLDB) released its quarterly earnings results on Friday, August, 10th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.01. View Solid Biosciences' Earnings History.

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release their next quarterly earnings announcement on Friday, November, 9th 2018. View Earnings Estimates for Solid Biosciences.

What price target have analysts set for SLDB?

7 brokerages have issued 1 year target prices for Solid Biosciences' shares. Their predictions range from $28.00 to $60.00. On average, they expect Solid Biosciences' stock price to reach $45.1429 in the next twelve months. This suggests that the stock has a possible downside of 12.7%. View Analyst Price Targets for Solid Biosciences.

What is the consensus analysts' recommendation for Solid Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences.

What are Wall Street analysts saying about Solid Biosciences stock?

Here are some recent quotes from research analysts about Solid Biosciences stock:
  • 1. According to Zacks Investment Research, "Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts. " (8/16/2018)
  • 2. Chardan Capital analysts commented, "We increase our SLDB PT to $60 (from $37.50) on recent reports of efficacy shown for AAV-based gene therapies (GTs) in Duchenne muscular dystrophy (DMD) across several ongoing trials, including Solid’s trial. Our PT increase is also driven by the 18 June announced resolution of the clinical hold on SGT-001. We believe early patient reports (see bullets below) suggest breakthroughs could be in progress for AAV- based gene therapies for DMD being developed by Therapeutics (unrated), and Pfizer (unrated). Positive early data from clinical trials from 3 different companies, to us, supports the utility of microdystrophin GT in a devastating disease with no effective approved therapies. therefore update our Chardan DMD Model (discussed below; see Figure 1), which drives our SLDB PT increase to $60." (6/24/2018)

Who are some of Solid Biosciences' key competitors?

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the folowing people:
  • Mr. Ilan Ganot, Co-Founder, CEO, Pres & Director (Age 44)
  • Ms. Jennifer Ziolkowski CPA, CFO, Treasurer & Assistant Sec. (Age 44)
  • Dr. Jorge A. Quiroz M.D., Chief Medical Officer (Age 48)
  • Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 47)
  • Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 46)

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

When did the company's lock-up period expire?

Solid Biosciences' lock-up period expired on Wednesday, July 25th. Solid Biosciences had issued 7,812,500 shares in its public offering on January 26th. The total size of the offering was $125,000,000 based on an initial share price of $16.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Has Solid Biosciences been receiving favorable news coverage?

Headlines about SLDB stock have trended somewhat positive on Friday, Accern reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Solid Biosciences earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media headlines about the company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Solid Biosciences.

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Boxer Capital LLC (7.84%), BlackRock Inc. (1.68%), Partner Fund Management L.P. (1.32%), Northern Trust Corp (0.31%), Spark Investment Management LLC (0.18%) and FMR LLC (0.17%). View Institutional Ownership Trends for Solid Biosciences.

Which major investors are selling Solid Biosciences stock?

SLDB stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc. and Birchview Capital LP. View Insider Buying and Selling for Solid Biosciences.

Which major investors are buying Solid Biosciences stock?

SLDB stock was purchased by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Partner Fund Management L.P., Spark Investment Management LLC, FMR LLC, Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp and Rhumbline Advisers. View Insider Buying and Selling for Solid Biosciences.

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $51.70.

How big of a company is Solid Biosciences?

Solid Biosciences has a market capitalization of $1.75 billion. The company earns $-52,110,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis. Solid Biosciences employs 60 workers across the globe.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.


MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel